AIM: To observe the clinical effect of conbercept combined with 25G minimally invasive vitrectomy in the treatment of proliferative diabetic retinopathy(PDR), and analyze the influencing factors of postoperative vitreous rehaemorrhage.

METHODS: Totally 179 eyes of 179 PDR patients confirmed and treated in our hospital from 2017-04/2019-11 were selected and grouped according to patients' condition and intention. 108 patients in the observation group underwent conbercept combined with 25G minimally invasive vitrectomy, while 71 patients in the control group underwent 25G minimally invasive vitrectomy only. The baseline data, intraoperative condition, best corrected visual acuity(BCVA), intraocular pressure, amplitude of N1 wave latency, central macular thickness(CMT)in the macular area before and after operation, and postoperative complications were compared between the two groups. The influencing factors of vitreous rehaemorrhage in PDR patients were analyzed.

RESULTS:The operative time, intraoperative bleeding rate, electrocoagulation rate, incidence of iatrogenic retinal hiatal aperture, the number of laser points and silicone oil filling rate of the observation group were all lower than those of the control group(P<0.05). After 6mo, BCVA(LogMAR), CMT and N1 wave latencies amplitude of the two groups were improved compared with those before operation, and the observation group was better than the control group(all P<0.05). The incidence of total complications in the observation group was lower than that in the control group(14.8% vs 40.8%, P<0.05). There were 31 cases and 31 eyes with vitreous rehaemorrhage after operation. Multivariate Logistic regression analysis showed that elevated HbA1c, vascular occlusion, proliferative retinal traction and no use of conbercept were risk factors for postoperative vitreous rehaemorrhage in PDR patients.

CONCLUSION: Conbercept combined with 25G minimally invasive vitrectomy in the treatment of PDR can reduce the intraoperative bleeding rate, reduce complications, shorten the operation time, and thus help to improve visual acuity and visual function. Effective control of blood glucose to reduce HbA1c level, intraoperative removal of fibrovascular hyperplasia membrane as much as possible to relieve retinal traction, and combined treatment with conbercept can reduce the risk of postoperative vitreous rehaemorrhage.